According to the FDA, leflunomide-induced liver injury is usually mild (ALT and AST elevation ≤ twice the upper limit of normal) and it rarely induces severe liver injury (ALT and AST elevation ≥ three times the upper limit of normal); furthermore, liver dysfunction can be reversed with dose reduction or treatment cessation (11). The gene discussed is GPT; the disease is Decreased liver function.